1Petridou I, Belechri M, Dessypris N, et al. Lep and BMI in relation to endometrial cancer risk[J]. Ann Nutr Metab, 2002, 46(2) :147-151.
2Luhn P, Dallal C M, Weiss J M, et al. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial [J]. Cancer Epidemiol Biomarkers Prey,2013,22(7) : 1304- 1312.
5Ashizawa N, Yahata T, Quan J, etal. Serum leptin adiponectin ratio and endometrial cancer risk in postmenopausai female subjects[J]. Gynecol Oncol,2010,119(1) :65-69.
6Cust A E, Kaaks R, Friedenreieh C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women[J]. J Clin Endocrinol Mctab,2007,92(1):255-263.
8Hlavana M, Kohut L, Lipkova J, et al. Relationship of resistin levels with endometrial cancer risk[J]. Neoplasma, 2011,58(2) :124-128.
9Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line[J]. J Biol Chem, 2003,278(31 ) : 28668-28676.
10Gao J, Tian J, Lv Y, et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERP, and PI3K/AKT pathways in human endometrial cancer cells[J]. Cancer Sci,2009,100(3) :389-395.
9Dominguez Coello S, Cabrera de Le6n A, Almeida Gonzcilez D, et al. Inverse association between serum resistin and insulin resistance in hurnans[J]. Diabetes Res Clin Pract, 2008,82 (2) : 256- 261.
10Hivert M F, Sullivan L M, Fox C S, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance[J]. J Clin Endoerinol Metab,2008,93(8) :3165 -3172.
1Cong Li, Gasser Jessica, Zhao Jessica, et al. Human adiponectininhibits cell growth and induces apoptosis in human endometrialcarcinoma cells, HEC-1-A and RL95 2[J]. Endocrine - RelatedCancer, 2007, 14(3):713-720.
2Murali R, Soslow RA, Weigelt B. Classifi cation of endometrial carcinoma: more than two types[J]. Lancet Oncol, 2014,15 (7) :e268-278.
3Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesi- ty and endometrial cancer risk: opportunities for prevention[J].Am J Obstet Gynecol,2011,205(6) :518-525.
4Contreras CM, Akbay EA, Gallardo TD, et al. Loss of Lkbl provokes highly invasive endometrial adenocarcinomas[J].Canc- er Res, 2008, 68(3):759-766.
6Lee SM, Choi JE, Na YK, et al. Genetic and epigenetic altera- tions of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers[J]. Lung Cancer, 2013, 81(2).194-199.
7Contreras CM, Akbay EA, Gallardo TD,et al. LKB1 inactiva- tion is sufficient to drive endometrial cancers that are aggressive yet highly responsive to roTOR inhibitor monotherapy[J]. Dis Model Mech, 2010,3(3) :181-193.
8Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K- AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis[J]. Mod Pathol, 2009, 22(4) :522-529.
9Co NN, Iglesias D, Celestino J, et al. Loss of LKB1 in high- grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53[J].Cancer, 2014,120(22) :3457-3468.
10Morton JP, Jamieson NB, Karim SA, et al. LKB1 haploinsuffi- ciency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest[J]. Gastro- enterol, 2010,139(2) :586-597.
